Thalidomide As Effective As Lenalidomide in Combo Regimen for Untreated Myeloma

Share this content:
Response, progression-free survival, and overall survival similar when comparing thalidomide, lenalidomide in untreated multiple myeloma.
Response, progression-free survival, and overall survival similar when comparing thalidomide, lenalidomide in untreated multiple myeloma.

Overall response rates, progression-free survival, and overall survival are similar when comparing melphalan, prednisone, thalidomide (MPT-T) and melphalan, prednisone, lenalidomide (mPR-R) in patients with untreated multiple myeloma, a recent study published online ahead of print in the journal Blood has shown. However, mPR-R was better tolerated and resulted in a better quality of life than MPT-T.

For the phase III trial, researchers compared MPT-T with mPR-R in 306 patients with untreated multiple myeloma. Patients had a median age of 75.7 years and were followed for a median of 40.7 months.

Results showed that median progression-free survival was 21 months and 18.7 months for MPT-T and mPR-R, respectively (HR = 0.84; 95% CI: 0.64, 1.09).

Moreover, overall survival was 52.6 months with MPT-T compared with 47.7 months with mPR-R (P=0.476) and response rates were 63.6% and 59.9%, respectively (P=0.557).

RELATED: Carfilzomib-Lenalidomide-Dexa + Lenalidomide in Pts with Smoldering or Newly Diagnosed MM

In regard to safety, grade 3 or higher non-hematologic toxicities were significantly more common in the MPT-T group than the mPR-R group (59.5% vs. 40.0%; P=0.001).

In addition, researchers found that patients treated with mPR-R reported a better quality of life by induction end than those treated with MPT-T (P=0.007).

Reference

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters